Peldesine (BCX 34) dihydrochloride is a potent, competitive, reversible, and orally active inhibitor of purine nucleoside phosphorylase (PNP), exhibiting IC50 values of 36 nM, 5 nM, and 32 nM against human, rat, and mouse red blood cell (RBC) PNP, respectively. Additionally, it acts as an inhibitor of T-cell proliferation with an IC50 of 800 nM. This compound shows promise for research into cutaneous T-cell lymphoma, psoriasis, and HIV infection [1] [2] [3] [4].

Peldesine (BCX 34; 0-50 μM; 72 hours; Jurkat cells) could inhibit the T-cell proliferation completely at a concentration of less than 10 μM, in the presence of dGuo (10 μM). In contrast, the B-cell proliferation is not affected by Peldesine [1]. Peldesine (BCX 34) suppresses T-cell immune reaction in an IL-2-independent manner, and this means that Peldesine might affect a late phase rather than an early stage in T-cell activation [1]. Peldesine also, in the presence but not in the absence of deoxyguanosine, inhibits human leukemia CCRF-CEM T-cell proliferation with an IC 50 of 0.57 μM but not rat or mouse T-cell proliferation up to 30 μM [3]. Cell Viability Assay [1] Cell Line: Jurkat cells Concentration: 0-50 μM Incubation Time: 72 hours Result: In the presence of 10 μM dCuo, had a complete inhibitory effect for T-cell lines.